Form 144 Filer Information

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK	0001801917
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	◉ LIVE ○ TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Roivant Sciences Ltd.
SEC File Number	001-40782
Address of Issuer	7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM SW1H 0DB
Phone	441-295-5950
Name of Person for Whose Account the Securities are To Be Sold	Venker Eric

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111	200000	7317764.00	722323015	10/28/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition	Name of Person from	Is this	Date Donor	Amount of Securities	Date of Payment	Nature of Payment *

		Transaction	Whom Acquired	a Gift?	Acquired	Acquired	
Common Shares	03/20/2025	Options Exercise - Grant Date 04/20/2022	Roivant Sciences Ltd.	☐	14023	03/20/2025	n/a
Common Shares	02/20/2025	RSU Grant 018305 - Grant date 05/20/2020	Roivant Sciences Ltd.	☐	8847	02/20/2025	n/a
Common Shares	01/20/2025	RSU Grant 018305 - Grant date 05/20/2020	Roivant Sciences Ltd	☐	8847	01/20/2025	n/a
Common Shares	03/24/2025	RSU Grant 018305 - Grant date 05/20/2020	Roivant Sciences Ltd	☐	11110	03/24/2025	n/a
Common Shares	03/20/2024	RSU Grant 018861 - Grant date 05/20/2021	Roivant Sciences Ltd	☐	4087	03/20/2024	n/a
Common Shares	11/16/2023	RSU Grant 018861 - Grant date 05/20/2021	Roivant Sciences Ltd	☐	3913	11/16/2023	n/a
Common Shares	10/18/2023	RSU Grant 018861 - Grant date 05/20/2021	Roivant Sciences Ltd	☐	3372	10/18/2023	n/a
Common Shares	06/02/2025	Options Exercise - Grant Date 04/20/2022	Roivant Sciences Ltd	☐	145801	06/02/2025	n/a

***** If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway, London X0 SW1H0DB	Common Shares	08/20/2026	13909	512407.56
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	08/28/2026	200000	7147087.91
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	09/30/2026	200000	7323556.00
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	10/20/2026	200000	7023513.39

144: Remarks and Signature

Remarks	The shares reported on this Form 144 will be sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/30/2026.
Date of Notice	10/28/2026
Date of Plan Adoption or Giving of	06/30/2026

Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Carmen Zamores as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Venker Eric

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)